Joint Formulary & PAD

Sertraline - Depression

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
 

Status 2

Green (see narrative)
Formulations :
  • Oral solution
Associated Icons :
Restrictions / Comments :
Important

100mg/5ml concentrate for oral solution - REQUIRES DILUTION

Reserve for patients who require a liquid formulation where an alternative SSRI liquid (citalopram drops, escitalopram drops or fluoxetine liquid) are not suitable.
Note – Dose must be diluted with 120mL of water, ginger ale, lemon/lime soda, lemonade or orange juice.

Dilution instructions are provided in the patient information leaflet: Sertraline 100mg/5ml concentrate for oral solution PIL

Documents :
 
 

Status 3

Green (see narrative)
Formulations :
  • Oral suspension
Associated Icons :
Restrictions / Comments :
Important

50mg/5ml oral suspension

Reserve for patients who require a liquid formulation only where:
- an alternative SSRI liquid (citalopram drops, escitalopram drops or fluoxetine liquid) are not suitable
- the patients is unable to manage the dilution of sertraline 100mg/5ml concentrate oral solution

PAD Profile

ChemicalSubstance :
Sertraline
Indication :
Depression
Group Name :
Keywords :
SSRIs, selective serotonin re-uptake inhibitors, antidepressants
Brand Names Include :
Lustral, Contulen
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Traffic Light Entries :
3

Committee Recommendations (1)

GENERIC Sertraline has been considered by the PCN and has been assigned a GREEN traffic light status.

NOTE - the branded product, Lustral, was considered BLACK at the PCN in May 2017.

Note - The Mood Hive and associated local depression and anxiety treatment guidelines have been removed from PAD.

Updated guidelines and resources for treating and managing depression in adults are being developed by Surrey & Borders Partnership. For current advice, in line with NICE guidance, please see the Clinical Knowledge Summaries - link provided below